Icon
+91 94997 68112
Login Register

Clobex - (SPRAY, TOPICAL 0.05%)

Clobetasol Propionate Galderma
SPRAY, TOPICAL 0.05%
Less Than $1000 mn
Less Than 5
Less Than 5
None None
More Than 5
More Than 5
Indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.
Yes
******* ** *** ***** ** **** **** ** **** ****** ***** *** ****** '*** ******** ** *** **, **** *** *** ************ *********. ***** ********* ******* * ********** **** ******* ***** ***** ******* ******** ******** & ******** *** *******. ***** ******* *** ***** * **** ** **** **** ****** ** ******* & *** ************ *********. ******* ******* ******** ******* **** *********** ******* ** ********* *** **** ****** ** *** ****** *** *** *******. **** ***** ***** ***** **** ** **** *** **** ****** *** *** ************. ** **** **** **** ***** *** **** **, ********** *** ******* **** ***** ***** *** ***** ** ********** *** *** *****.
Clobex Patent 1
******* *******
***** *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** *, ****
***** ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
  1. ***, **** : ******* ******** ******** ***** *** ****** ****** **** *.**% ******* ***** ** ****** *** ****** *******.
  2. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  3. ***, **** : ******* ******** ******** ***** *** ****** ****** **** *.**% ******* ***** ** ****** *** ****** *******.
  4. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  5. ***** *, **** : ******** & ******* ******* * **********. **** ********** *** ********* ***** *** ***** ****** ********* ****** ** *******'* *****.
  6. **** **, **** : ******* ******** ******** *** ******** *** *******.
  7. **** **, **** : ******* ******** *******.
  8. *** **, **** : ******** ***** * **** ******* ***** ** ***** ***** **** ** **** ****** '***.
  9. *** **, **** : ********** *** ********* **** ***** ***** *** ***** ** ********** *** *** *****.

Clobex - (Shampoo, topical, 0.05%)

Clobetasol Propionate Galderma
Shampoo, topical, 0.05%
Less Than $1000 mn
Less Than 5
More Than 5
More Than 5
 None
More Than 5
More Than 5
Used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis
Yes
******* ** *** ***** ** **** **** ** **** ******* '*** & '*** ******** ** *** **, **** & *** *, **** ************ & *** ************ *********. ******* ******* ******* * ********** **** ********. ******* *** ** ***** ************** ** ********** *************** ******** ******* **** ** ****** ** ******* ********* ******** ****** *** ********** ** ******. ******* ******* *** ******* ** ******** **** ***** *** *** ******* *** *** **** *********** ***** ******* ****. ** ***** ** ** **** ******* *** *** *** ******** *** *******.
Clobex Patent 1 Patent 2
******* ******* *******
******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ******* ******** ******** ** *** *, ****
******* ** \ ** ***, **** ******* ******** ******** ** *** **, ****
  1. *** *, **** : ******* ***** * **** ** **** ****** *** ****** ******* & *******. ******** ***** * **** ******* ******* ** ******** ***** ** ******** ******** ** *****, **** ***** ********.
  2. *** *, **** : ********** **** ******* *** *******.
  3. ****, **** : ******* ******** ******** ***** *** **** ** ****** **** *.**% ******* *** ******* & *******.
  4. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  5. **** *, **** : ******* ******** ********.
  6. *** *, **** : ********** **** ******* *** *******.

Clobex - (0.05% lotion, Topical)

Clobetasol Propionate Galderma
0.05% lotion, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
super-high potent corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older
Yes
******* ** *** ***** ** **** **** ** **** ****** ****** *** ****** '*** (******** ** **** **, ****) ************ *** ********* ** ********. ******* ********** **** ******* *** ********* (******** * **********). ******* ******** ** ******** *** ******** ****** ******* *** ****** ** ****. ***** *** (****) *** ********* ****** **** ***** * **** ** **** ****** *** **** ****** (** *** *******) *** **** ************ *********. ********** *** ******* **** ***** *** ********* ** **** ********* ** *** ***** ** ***** **** *** ********* ******** *** ****** ****** ** ****,
Clobex Patent 1
******* *******
*** (****) *******
******** (*** ****) *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** *, ****
*** (****) ** \ ** *** **** ******* ******** ******** ** *** *, ****
******** (*** ****) ** \ ** *** *, **** ******* ******** ******** ** *** **, ****
  1. ***, **** : ******* ******** ******** ***** *** **** ** **** *.**% ****** *** ****** *******.
  2. ****, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  3. ***, **** : ******** *********** ********* *** **** ******* ******* & ******* ******** ********.
  4. ***, **** : **** ******** ******** ***** *** **** ** **** *.**% ****** *** ****** *******.
  5. ***, **** : ******** ***** * **** ******* **** ** ******** ******** ***** ** *****.
  6. **** *, **** : ******* ******** ********.
  7. *** **, **** : ********** *** ********* **** **** ***** *** ***** ** ********* *** *** *****. ** ****** **** ** **** ****** *** **** ***** *******.
  8. *** *, **** : ******** ***** * **** ******* ******** (*** ****) ** ******** ***** ** ******** ******** ** ***** ****** ******** ** *** ******* ***** **** ** **** ****** '***.
  9. *** **, **** : ********** *** ********* **** ******** (*** ****) ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.